<DOC>
	<DOCNO>NCT01190020</DOCNO>
	<brief_summary>Lubiprostone , chloride channel activator , show improve symptom chronic constipation , largely enhance chloride-rich intestinal fluid secretion . Whether Lubiprostone effect colonic methanogenesis know . The investigator hypothesize effect Lubiprostone may part due effect alter colonic flora , particularly methanogenic flora . By alter colonic stasis stool efficient clearance digestive residue , investigator anticipate Lubiprostone may either inhibit promote well excretion methanogenic flora , thereby decrease gut load methane produce bacteria . In turn , may lead enhance colonic smooth muscle contraction increase rate spontaneous bowel movement reduction constipation symptom . The aim investigate effect Lubiprostone intestinal methane production bowel symptom patient chronic constipation , perform randomize , double blind , placebo control study .</brief_summary>
	<brief_title>Effect Lubiprostone Methanogenesis Bowel Function Chronic Constipation .</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Constipation define Rome III criteria13 . Patients must symptoms &gt; 3 days/month past three month report least two follow symptom ≥ 25 % time : straining , lumpy hard stool , sensation incomplete evacuation , sensation anorectal obstruction/blockage , use manual maneuver , &lt; 3 bowel movements/week . Also , insufficient criterion IBS , rarely loose stool without use laxative . ≥ 3 ppm methane value baseline1 , 2 ( sugar load ) . Patients take drug know constipate exclude ask discontinue medication least 2 week reassess . For example , recommend patient take calcium channel antagonist contact respective primary care physician explore alternative medication hypertension beta blocker ACEinhibitors . If calcium channel antagonists able discontinue , patient rescreened least two week medication discontinue . If patient longer meet inclusion criterion , exclude study . Patients remain constipated eligible enrollment . Patients comorbid illness severe cardiovascular disease , chronic renal failure , previous gastrointestinal surgery except cholecystectomy appendectomy Patients neurologic disease multiple sclerosis , stroke , spinal cord injury , problem cognizance , i.e . minimental score &lt; 15 and/or legally blind exclude . Women pregnant likely conceive course study exclude . Urinary pregnancy test perform woman childbearing potential prior enrollment xray abdomen . Patients Hirschsprung ' disease , active local anorectal problem anal fissure , bleed hemorrhoid , Crohn 's , colitis , colon cancer . Patients alternate constipation diarrhea fulfill RomeIII criterion irritable bowel syndrome . Recent antibiotic use ( last 6 week ) . Patients use laxative , PEG Tegaserod unwilling discontinue medication least 2 week prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>